Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

NCT07389499 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT07389499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07389499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Lead sponsor
Grit Biotechnology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2027
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis (aav)/anca-associated glomerulonephritis (aagn), iga nephropathy (igan), membranous nephropathy, proliferative glomerulonephritis with monoclonal immunoglobulin deposits, refractory podocytopathy